Groundbreaking research presented at UEG Week 2024 introduces a new treatment approach for type 2 diabetes (T2D) combining a procedure called ReCET with semaglutide, resulting in the elimination of insulin therapy for 86% of patients. This innovative strategy targets the root cause of T2D by improving the body’s sensitivity to its own insulin. The study included 14 participants who successfully completed the ReCET procedure and maintained glycemic control without needing insulin therapy. The treatment was well-tolerated, with plans for larger trials to validate the findings and evaluate the underlying mechanisms. This approach offers potential for a compliance-free and disease-modifying treatment for T2D.
Source link
Novel procedure combined with semaglutide may eliminate insulin dependency in type 2 diabetes
